Linkedin X-twitter Instagram

Investor Relations

Investing in the Scalable Future of Cellular Medicine

Request Investor Deck

Join the Regenerative Revolution with Chiron Therapeutics

  • The Problem: low-yield adult stem cell production, iPSC Safety & Cost Risks.
  • The Solution: SIST™ High-Yield & Low Cost Technology.
  • The Value: De-risked Commercialization.

With the global regenerative medicine market projected to reach $48.83 billion by 2034 (Precedence Research), Chiron is uniquely positioned to capture significant market share—delivering both near-term impact and long-term value.

Addressing Critical Market Needs

  • Safety First: Non-genetic reprogramming eliminates tumor risks associated with iPSCs
  • Scalability: 100X expansion of adult stem cells enables commercial-scale production
  • Clinical Efficiency: Accelerated regulatory pathway compared to genetically modified cells
  • Cost-Effectiveness: Lower manufacturing costs translate to improved profit margins

WHY INVEST IN CHIRON?

  • Extensive R&D validation.
  • Peer-reviewed publications.
  • Successful proof-of-concept in cartilage regeneration.
  • Robust international patent protection.
  • And a strategic focus on the lower-regulatory, high-growth regenerative cosmetics market.

This strong foundation of technical credibility, IP defensibility, and a clear market‑entry path positions Chiron for substantial upside in a rapidly expanding sector.

Capturing a $48B Market Opportunity

$12.35 billion market (2023) is projected to grow at a CAGR of 11.2% by 2030, positioning Chiron to lead the adult stem cells market.

Validated Technology with Strong IP Protection

The investment is supported by a proven, non‑transgenic SIST method for high‑yield, scalable adult stem cell production, protected by a secured PCT international patent filing, with ongoing enhancements to optimize exosome purity and yield.

De-Risked Path

A strategic "cosmetic ingredients" focus with no therapeutic claims for faster market entry with lower regulatory hurdles

Strategic Market Advantage

The rapidly growing global regenerative medicine and aesthetics markets present a substantial opportunity for Chiron's innovative technology.

Anti-Aging Skincare Market Opportunity

Key Market Drivers

Rising demand for non-invasive, science-backed solutions among aging populations worldwide. Asia Pacific shows fastest growth potential.

$ 0 B

2034 Projection

$ 0 B

2025 Market Size

% 0

North America Share

Chiron Therapeutics is pioneering a new era in skincare and skin rejuvenation through stem cell–derived exosomes.

Adult Stem Cells Market Growth

The adult stem cells market is projected to reach $12.4 billion by 2023, with steady growth to 2030 at a CAGR of 11.2%. This trend highlights the increasing demand for regenerative medicine solutions like those offered by Chiron Therapeutics.

11.2%

Global Market CAGR, 2024-2030

Autologous focus

Fastest growing segment in the market

Key Market Drivers– Anti-Aging Skincare

  • Growing Aging Population Worldwide
  • Shift Toward Science-Backed Beauty
  • Premiumization of Skincare
  • Demand for Non-Invasive Solutions
  • Rise of Exosomes as Next-Gen Actives
  • Faster Regulatory Path

Key Market Drivers– Adult Stem Cells & Regenerative Medicine

  • Unmet Clinical Need
  • Manufacturing Bottlenecks
  • Growing Investment in Regenerative Medicine
  • Rising Demand for Regenerative Treatments

Chiron's Competitive Edge

  • Proprietary, IP-Protected Platform
  • Solves the Industry’s Core Bottleneck
  • De-Risked Market Entry Strategy
  • Dual-Market Upside
  • Capital-Efficient Growth Model
  • Attractive Partner Profile

SIST Breakthrough: IP-Licensed Innovation with Unmatched Potential

Chiron's SIST™ technology offers a clinically validated, transgene-free solution to the expansion of adult stem cells—100x more efficient than traditional methods—while avoiding the complex FDA hurdles of iPSC-based therapies.

Safety Advantage

Avoids iPSC FDA hurdles (e.g., tumorigenicity risks delaying approvals) by using transgene-free approach with adult stem cells

Production Efficiency

100x expansion of adult stem cells enables cost-effective manufacturing at scale, addressing the massive gap in clinical demand

Strategic Validation: Corning Collaboration

Strategic Collaboration with Corning

Sponsorship

Corning will be providing support via the supply of Elplasia plates for adult stem cell manufacturing.

Elplasia Plates

Enables us to optimize the scale up of SIST based production of adult stem cells. They cost-effectively drive Chiron's ability to manufacture adult stem cells at scale.

Regulatory Impact

Critical for preclinical data generation and eventual FDA/Health Canada filings.

Seed Round

  • Raise: $4M
  • Valuation: $20M Pre-money

First Year

  • Budget: ~$1.67M (~42% of $4M)
  • Allocation:
  • Recruitment
  • Lab set up
  • Product Development
  • G&A
  • Focus: Onboard full team, Secure lab Space, Lab set up

Second Year

  • Budget: ~$1.6M (~40% of $4M)
  • Allocation:
  • Payroll
  • Lab Operations
  • Regulatory/Legal
  • G&A
  • Focus: Upgrade equipment, Preparing for pilot production (6K units target)

Third Year

  • Budget: ~$1.62M (18% of $4M + From Revenue)
  • Allocation:
  • Payroll
  • Lab Operations
  • Regulatory/Legal
  • G&A
  • Focus: Manufacturing scale-up, Expansion: Lab space, Team and Infrastructure. Launch pilot product and Prepare for the Next Scale up in the Fourth Year.

Our Venture Journey

Connect With Our Investor Team

Behzad Yeganeh, Ph.D.

Founder & Chief Executive Officer

Dr. Behzad Yeganeh is the visionary Founder and CEO of Chiron Therapeutics, a seasoned biotech leader with over 15 years of experience translating complex biological discoveries into commercially viable assets. A two-time founder and serial entrepreneur, Dr. Yeganeh combines deep technical expertise in molecular biology with a proven track record of launching successful ventures anchored by proprietary intellectual property.

As the inventor of the revolutionary SIST technology, Dr. Yeganeh achieved a breakthrough high yield in generation of adult stem cell without genetic modification. This IP-licensed invention positions Chiron Therapeutics at the forefront of regenerative innovation, unlocking transformative therapeutic and cosmetic applications for adult stem cells.

Dr. Yeganeh’s leadership extends from bench to pre-clinical validation, including extensive experience in GMP manufacturing and regulatory strategy, notably with Health Canada. He has demonstrated a strong ability to secure non-dilutive funding and drive R&D strategies that bridge the gap between scientific innovation and market reality.

Linkedin